LONDON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr. David Ebsworth, Chairman of the Company, has notified the Company that he has purchased a further 75,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”) at a total purchase price of £32,500, at prices between 42 and 45 pence per Ordinary Share and an average price of 43.33 pence.

Following the purchases, Dr. Ebsworth will have an interest in the Company of 370,387 Ordinary Shares, representing 0.35% of the Company’s issued share capital.

Further information is provided below in accordance with the requirements of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1Details of the person discharging managerial responsibilities/person closely associated
a)NameDavid Ebsworth
2Reason for the notification

a)

Position/status
Chairman
b)Initial notification/AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerona Pharma plc
b)LEI

 
213800EVI6O6J3TIAL06

 


4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary Shares of 5 pence each  
 Identification codeGB00BYW2KH80  
b)Nature of the transactionDavid Ebsworth purchased 75,000 Ordinary Shares  
     
c)Price(s) and volume(s)DatePrice(s)Volume(s)
  11 November 201942 pence25,000
  12 November 201943 pence25,000
  13 November 201945 pence25,000
d)Aggregated information75,000 Ordinary Shares  
 -  Aggregated volume43.33 pence  
 -  Price   
e)Dates of the transactionsAs per 4c) above  
f)Place of the transactionsLondon Stock Exchange, AIM  

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officerinfo@veronapharma.com
Victoria Stewart, Director of Communications 
  
N+1 Singer
(Nominated Adviser and UK Broker)
Tel: +44 (0)20 3283 4200
Aubrey Powell / George Tzimas (Corporate Finance) 
Mia Gardner (Corporate Broking)